Evidence map›Paper›PMID 32942984›Full record

ArticleJournal of neurodevelopmental disorders2020

Functional characterization of rare NRXN1 variants identified in autism spectrum disorders and schizophrenia.

Kanako Ishizuka, Tomoyuki Yoshida, Takeshi Kawabata, Ayako Imai, Hisashi Mori, Hiroki Kimura, Toshiya Inada, Yuko Okahisa, Jun Egawa, Masahide Usami and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Autism spectrum disorder and schizophrenia: An updated conceptual review.Autism research : official journal of the International Society for Autism Research · 2022
    Pooled it
  2. Review
  3. Genetic alterations in SUPT6H are associated with neurodevelopmental disorders.Biochimica et biophysica acta. Molecular basis of disease · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Landscape ofJournal of clinical medicine · 2024
    Review
  16. Review
  17. Open medicine (Warsaw, Poland) · 2024
    Review
  18. Article
  19. Dysregulation of Synaptic Plasticity Markers in Schizophrenia.Indian journal of clinical biochemistry : IJCB · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Kanako IshizukaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan.
Tomoyuki YoshidaDepartment of Molecular Neuroscience, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, 9300194, Japan.
Takeshi KawabataInstitute for Protein Research, Osaka University, Osaka, 5650871, Japan.
Ayako ImaiDepartment of Molecular Neuroscience, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, 9300194, Japan.
Hisashi MoriDepartment of Molecular Neuroscience, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, 9300194, Japan.
Hiroki KimuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan.
Toshiya InadaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan.
Yuko OkahisaDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 7008558, Japan.
Jun EgawaDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 9518510, Japan.
Masahide UsamiDepartment of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Chiba, 2728516, Japan.
Itaru KushimaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan.
Mako MorikawaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan.
Takashi OkadaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan.
Masashi IkedaDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 4701192, Japan.
Aleksic BrankoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan.
Daisuke MoriDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan. d-mori@med.nagoya-u.ac.jp.ORCID 0000-0002-9072-2546
Toshiyuki SomeyaDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 9518510, Japan.
Nakao IwataDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 4701192, Japan.
Norio OzakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 4668550, Japan.
Nagoya University · JPUniversity of Toyama · JPFujita Health University · JPNiigata University · JPNational Center for Global Health and Medicine · JPOkayama University · JPProtein Research Foundation · JP

Funding

Japan Agency for Medical Research and Development JP18dk0307075Japan Agency for Medical Research and Development JP18dk0307081Japan Agency for Medical Research and Development JP18dm0107087Japan Agency for Medical Research and Development JP18dm0207005Japan Agency for Medical Research and Development JP19am0101066Japan Agency for Medical Research and Development JP19dk0307081Japan Agency for Medical Research and Development JP19dm0107087Japan Agency for Medical Research and Development JP19dm0207075hJapan Society for the Promotion of Science JP17H06747Japan Society for the Promotion of Science JP18H04040Japan Society for the Promotion of Science JP18K15513Japan Society for the Promotion of Science JP18K19511
6 · The paper itself

Abstract

backgroundRare genetic variants contribute to the etiology of both autism spectrum disorder (ASD) and schizophrenia (SCZ). Most genetic studies limit their focus to likely gene-disrupting mutations because they are relatively easier to interpret their effects on the gene product. Interpretation of missense variants is also informative to some pathophysiological mechanisms of these neurodevelopmental disorders; however, their contribution has not been elucidated because of relatively small effects. Therefore, we characterized missense variants detected in NRXN1, a well-known neurodevelopmental disease-causing gene, from individuals with ASD and SCZ.

methodsTo discover rare variants with large effect size and to evaluate their role in the shared etiopathophysiology of ASD and SCZ, we sequenced NRXN1 coding exons with a sample comprising 562 Japanese ASD and SCZ patients, followed by a genetic association analysis in 4273 unrelated individuals. Impact of each missense variant detected here on cell surface expression, interaction with NLGN1, and synaptogenic activity was analyzed using an in vitro functional assay and in silico three-dimensional (3D) structural modeling.

resultsThrough mutation screening, we regarded three ultra-rare missense variants (T737M, D772G, and R856W), all of which affected the LNS4 domain of NRXN1α isoform, as disease-associated variants. Diagnosis of individuals with T737M, D772G, and R856W was 1ASD and 1SCZ, 1ASD, and 1SCZ, respectively. We observed the following phenotypic and functional burden caused by each variant. (i) D772G and R856W carriers had more serious social disabilities than T737M carriers. (ii) In vitro assay showed reduced cell surface expression of NRXN1α by D772G and R856W mutations. In vitro functional analysis showed decreased NRXN1α-NLGN1 interaction of T737M and D772G mutants. (iii) In silico 3D structural modeling indicated that T737M and D772G mutations could destabilize the rod-shaped structure of LNS2-LNS5 domains, and D772G and R856W could disturb N-glycan conformations for the transport signal.

conclusionsThe combined data suggest that missense variants in NRXN1 could be associated with phenotypes of neurodevelopmental disorders beyond the diagnosis of ASD and/or SCZ.

Indexed as

Autism Spectrum DisorderSchizophreniaCalcium-Binding ProteinsExonsHeterozygoteHumansMutationNeural Cell Adhesion MoleculesCalcium-Binding ProteinsNeural Cell Adhesion MoleculesNRXN1 protein, humanAutism spectrum disordersGenotype-phenotypeMissense variantsNeurodevelopmental disorderNRXN1SchizophreniaTargeted resequencingUltra-rare variants

Identifiers

PMID32942984
PMCPMC7496212
OpenAlexW3085512855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.